• First actively managed tokenized equity fund extending tokenization beyond single assets to professionally managed public equity strategies
• Tokenized on Ethereum and distributed via DigiFT, providing eligible investors a regulated on-chain way to invest
• Advances institutional adoption of tokenization, building on BNY’s deep investment expertise and DigiFT’s track record of bringing Tier-1 asset manager strategies on-chain

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — DigiFT, a regulated on-chain exchange for institutional real-world assets, today announced the introduction of DigiFT U.S. Equity Income Fund (“bEQTY”), the first actively managed tokenized U.S. equity income fund on the Ethereum public blockchain.

The launch of bEQTY, which is eligible for accredited investors, represents a significant milestone in the evolution of tokenization—marking a shift from early experimentation with blockchain-based financial instruments toward enabling investors to construct more complete, portfolio-relevant strategies on-chain.

BNY serves as the investment manager for the underlying traditional U.S. equity income strategy which extends tokenization into actively managed public equities. This launch demonstrates how regulated on-chain infrastructure is advancing beyond initial applications to address more sophisticated areas of the capital markets. 

Tokenization as institutional portfolio infrastructure

Public equities remain a core component of institutional portfolios. Tokenization introduces a digitally native form factor that enables programmable settlement, enhanced transparency, and more streamlined lifecycle management—without changing the underlying investment strategy or governance framework.

By representing equity income strategies on regulated on-chain infrastructure, eligible investors gain greater flexibility in how sophisticated financial instruments are held, transferred, and integrated into portfolios, supporting more agile capital management.

For Web3-native allocators, as on-chain treasuries and funds mature, there is growing interest in incorporating assets that introduce exposure to the real-economy and are less correlated with crypto-native market cycles.

The launch also illustrates how regulated on-chain marketplaces can support wider institutional participation by enabling eligible investors to access the strategy through DigiFT’s regulated framework.

Henry Zhang, Founder and Group CEO of DigiFT, said: “For years, tokenization has been about proving the technology. This launch proves its use case. By bringing an actively managed equity income strategy on-chain within a regulated market, we’re demonstrating how blockchain infrastructure is becoming part of mainstream institutional finance.”

Doni Shamsuddin, Head of Asia Pacific, BNY Investments, said: “We are thrilled to work with DigiFT in bridging traditional finance and emerging on-chain solutions for institutional investors. Leveraging BNY’s deep investment capabilities, we enable a professionally managed portfolio on blockchain — anchored in established trust, scale, and governance.”

From experimentation to portfolio-relevant strategies

Tokenization has gained early traction in short-duration and cash-like instruments, demonstrating the operational benefits of blockchain within regulated frameworks.

As tokenization matures, extending its capabilities into actively managed public equities represents a natural next phase—moving beyond single assets toward actively managed strategies within regulated market infrastructure.

About DigiFT

DigiFT is a next-generation exchange for tokenized real-world assets (RWAs), licensed by the Monetary Authority of Singapore (MAS) and the Hong Kong Securities and Futures Commission (SFC). The platform offers end-to-end digital asset services—including tokenization, issuance, distribution, trading, and instant liquidity provision—purpose-built for institutional RWAs. Trusted by global financial institutions, DigiFT is the on-chain tokenization and distribution partner for leading asset managers such as Invesco, UBS Asset Management, and Wellington Management. For more information, visit https://digift.io

About BNY

BNY is a global financial services platforms company at the heart of the world’s capital markets. For more than 240 years BNY has partnered alongside clients, using its expertise and platforms to help them operate more efficiently and accelerate growth. Today BNY serves over 90% of Fortune 100 companies and nearly all the top 100 banks globally. BNY supports governments in funding local projects and works with over 90% of the top 100 pension plans to safeguard investments for millions of individuals. As of December 31, 2025, BNY oversees $59.3 trillion in assets under custody and/or administration and $2.2 trillion in assets under management.

BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). Headquartered in New York City, BNY has been named among Fortune’s World’s Most Admired Companies and Fast Company’s Best Workplaces for Innovators. Additional information is available on www.bny.com. Follow on LinkedIn or visit the BNY Newsroom for the latest company news.

Disclaimers

DigiFT and/or its affiliates endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy or reliability, and accept no liability (whether in tort, contract, or otherwise) for any loss or damage arising from any inaccuracy or omission, or from any decision, action, or non-action based on or in reliance upon the information contained in this material.

This information does not constitute an invitation, recommendation, or offer to subscribe for, purchase, or enter into any transaction involving the above-mentioned product/service or any other services mentioned. The above-mentioned product/service is only available to Accredited Investors, Professional Investors, and Institutional Investors through authorised regulated intermediaries.

Before making any investment decision, please seek independent legal and financial advice. Clients intending to trade this product are reminded of the risks associated with such products and should carefully assess their investment objectives, risk appetite, financial situation, and particular needs before making any investment decision.

This content is for general informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any product or service. Eligibility to access or invest in any products mentioned is subject to applicable laws and investor qualification requirements. DigiFT products and services are available only through authorised and regulated intermediaries to eligible investors. Readers should seek independent legal, financial, and tax advice before making any investment decision.

BNY and/or its affiliates are not the issuer, distributor, placement agent of DigiFT U.S. Equity Income Fund, and DigiFT U.S. Equity Income Fund is not sponsored, recommended, endorsed, guaranteed or otherwise financially backed by BNY and/or its affiliates.

Formulated with 12 pharmacopoeia-grade botanicals, the new cream is designed to support eczema-prone and sensitive skin for young children and adults seeking a non-steroidal option.

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — CI Labs, a Singapore-based wellness brand focused on gentle and effective skincare, announced the launch of its CI Labs Eczema Relief Cream, a non-steroidal formulation developed to support eczema-prone and sensitive skin.

Formulated with 12 pharmacopoeia-grade botanicals traditionally used to help soothe irritation and support skin comfort, the cream is designed for families looking for a gentle, non-steroidal alternative to steroid-based products.

Developed in collaboration with certified skincare laboratories and inspired by traditional herbal medicine, CI Labs Eczema Relief Cream is free from steroids, parabens, and artificial fragrances. It is designed for use by children and adults, and is suitable for infants from six months of age when used as directed.

Each production batch undergoes independent third-party screening by ALS Ltd, a publicly listed global testing laboratory, for a comprehensive panel including steroids, antihistamines, antibiotics, heavy metals, poisons, and other potential contaminants.

Founded from a Personal Journey to Find Gentler Care

CI Labs was founded following the personal journey of its founder, who spent over two decades managing chronic eczema and the longer-term concerns often associated with steroid-based care. The turning point came when his young daughter began showing early signs of eczema, prompting a renewed search for a gentler, non-steroidal option suitable for long-term family use.

Driven by this mission, the CI Labs team collaborated with certified laboratories, senior medical professionals, and traditional medicine practitioners to research and refine a formulation grounded in traditional herbal knowledge and modern quality standards. Particular emphasis was placed on ingredient consistency, sourcing integrity, and safety, recognising that botanical quality can depend on geo-authenticity, purity, and controlled cultivation and processing practices.

This approach ultimately led to the development of CI Labs Eczema Relief Cream — a formulation designed to support skin comfort while meeting stringent quality and testing standards.

A CI Labs spokesperson said: “Families today want solutions that are effective yet gentle enough for young children. CI Labs was created to bridge that gap with a formulation that brings both comfort and confidence. Our mission is simple: it’s where hope meets healing.”

A Carefully Curated Blend of 12 Pharmacopoeia-Grade Botanicals

Each CI Labs Eczema Relief Cream formulation is crafted using botanicals selected for their traditional skincare applications, with strict controls on geo-authenticity, genetic integrity, and environmental contaminants at source. Key ingredients include:

• Chamomile (Matricaria chamomilla): Traditionally used to help soothe irritated-looking skin.
• Purple gromwell root (Lithospermum erythrorhizon): Traditionally used in topical preparations for skin comfort.
• Tea tree (Melaleuca alternifolia): Commonly used in skincare for its cleansing properties.
• Chinese gall (Rhus chinensis): Traditionally valued for its astringent properties.
• Golden larch bark (Pseudolarix kaempferi): Traditionally used to help relieve itchiness.
• Smilax glabra: Traditionally used to support skin clarity.
• Arisaema (Arisaema erubescens): Traditionally used in preparations associated with “detumescence” (swelling-related support).
• Chinese mint (Mentha haplocalyx): Traditionally valued for a cooling skin feel.
• Grape leaf (Vitis vinifera): Traditionally associated with venous circulation support.
• Evodia (Evodia rutaecarpa): Traditionally used and studied for anti-inflammatory support.
• Red sage root (Salvia miltiorrhiza): Traditionally used to support circulation.
• Cnidium monnieri: Traditionally used to help relieve itchiness.

Together, these botanicals form a modern, non-steroidal skincare formulation designed to support skin comfort and resilience.

Formulated for Singapore’s Climate

Recognising that heat and humidity can aggravate sensitive skin, CI Labs Eczema Relief Cream is designed to:

• Absorb quickly without greasiness
• Provide a light, cooling skin feel
• Support the skin barrier against sweat- and heat-related irritation

Availability & Pricing

CI Labs Eczema Relief Cream is now available via:

• Official Online Store: www.mycilabs.com
• TikTok Shop: @mycilabs
• Instagram: @mycilabs

Product Formats & Pricing:

• 30ml Full-Size Bottle: SGD 69
• Triple Pack (3 × 30ml): SGD 177
• Subscription Plan: SGD 49 per bottle
  (Minimum six-month subscription; billed per renewal cycle.)

About CI Labs

CI Labs is a Singapore wellness brand dedicated to creating gentle, effective, and science-supported skincare inspired by traditional herbal wisdom. All products are developed in certified laboratories using pharmacopoeia-grade botanicals and dermatologist-guided formulation standards.

CI Labs’ guiding mission is simple: Where Hope Meets Healing — supporting comfort, confidence, and care for families managing sensitive and eczema-prone skin.

HONG KONG, Jan. 26, 2026 /PRNewswire/ — AXA Hong Kong and Macau (“AXA”) is pleased to announce the successful completion of the re-domiciliation of AXA China Region Insurance Company (Bermuda) Limited (“the Company”) from Bermuda to Hong Kong, under the re-domiciliation regime introduced by Hong Kong Special Administrative Region Government. Effective 26 January 2026 (today), the Company has been renamed to AXA China Region Insurance Company (Hong Kong) Limited.

This milestone demonstrates AXA’s ongoing commitment to serving customers in the region, reaffirming Hong Kong’s role as a vital financial centre.  As one of the first insurers to undertake this initiative, AXA reinforces its long-standing presence and enhances its operational capabilities, positioning itself for sustainable growth and long-term success. Following the completion of the re-domiciliation of the Company in Hong Kong, in the week commencing 2 February 2026, the Company intends on applying to the relevant authorities in Macau for updating its Macau branch name.

Sally Wan, Chief Executive Officer, AXA Greater China, said, “The re-domiciliation underscores our strong confidence in Hong Kong’s strategic importance and growth potential, and reflects our unwavering commitment to serving customers with resilience and innovation. Leveraging Hong Kong’s robust economy and its role as a regional hub for insurance and risk management, we are confident that AXA’s long-term success will continue to advance. Looking ahead, we remain committed to creating long-term value for our customers, partners, and the community, while actively pursuing sustainable growth.”

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 50 markets and serving 95 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers’ needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. We are proud to be the first to address the importance of mental health through different products and services and thought leading iconic research. Our overall Sustainability Strategy, with emphasis on climate strategy and biodiversity commitment, is developed based on TCFD recommendations. We are committed to integrating environmental, social and governance factors across our business and strive to contribute to a sustainable future through 3 distinct roles – as an investor, an insurer and an exemplary company.

THIS PRESS RELEASE IS AVAILABLE ON AXA’S WEBSITE: AXA.COM.HK 

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS
Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Universal Registration Document for the year ended December 31, 2019, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

SINGAPORE, Jan. 26, 2026 /PRNewswire/ — Most enterprises believe they have observability because they have dashboards. In reality, IT teams are still operating with blind spots across critical systems, leading to slower incident response and inconsistent user experiences.

New insights from a technology position paper by Neurones IT Asia reveal that only 9% of enterprise software applications today are fully observable end-to-end. As architectures expand across hybrid and multi-cloud environments, the observability challenge is no longer about collecting data but turning telemetry into operational clarity.

Modern observability runs on metrics, logs, and traces. Yet for many teams, signals remain fragmented across tools and platforms, increasing alert noise and slowing investigations. The next phase of observability is about improving the signal-to-noise ratio, correlating telemetry across infrastructure and applications, and isolating the true root cause across distributed services and dependencies.

This is where AI-driven observability is becoming the new reality of IT operations. Instead of reacting to symptoms after users are impacted, AI can help teams correlate events across systems, detect anomalies earlier, and accelerate root-cause analysis through context-driven insights. With the right implementation, organizations can amplify decision-making, reduce unnecessary escalations, and shorten mean time to resolution by up to 70%.

Titled “From Monitoring to Intelligence: How Observability and AI Redefine IT Operations”, the paper explores why observability adoption remains limited across the region and what leaders can do to close the gap.

Download the position paper here.

For more information, please contact: marketing@neurones-it.asia

About Neurones IT Asia
Neurones IT Asia helps businesses drive growth and resilience through IT Consulting, Transformation and Managed Services across Asia Pacific. Headquartered in Singapore, with offshore capabilities in India and regional presence in Hong Kong SAR and Australia, we have successfully delivered over 1,000 tailored technology solutions in Platform, Data and Software Engineering. Working alongside an ecosystem of leading technology partners, we are committed to empowering businesses to achieve their tech ambitions with confidence. Neurones IT Asia is part of the Neurones IT Group, a French leader in Digital Transformation and Operation. Learn more about our services and follow us on LinkedIn.

Contact: Neurones IT Asia
marketing@neurones-it.asia